Granahan Investment Management LLC Sells 44,259 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Granahan Investment Management LLC trimmed its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 463,110 shares of the company's stock after selling 44,259 shares during the period. Granahan Investment Management LLC owned approximately 0.64% of Kiniksa Pharmaceuticals worth $9,160,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of KNSA. Teacher Retirement System of Texas grew its stake in Kiniksa Pharmaceuticals by 7.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after buying an additional 719 shares during the last quarter. Martingale Asset Management L P grew its stake in shares of Kiniksa Pharmaceuticals by 1.9% during the fourth quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock worth $976,000 after acquiring an additional 900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after acquiring an additional 1,004 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock valued at $1,798,000 after purchasing an additional 1,100 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its stake in Kiniksa Pharmaceuticals by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock worth $457,000 after purchasing an additional 1,374 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on KNSA shares. Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Finally, Wedbush restated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals currently has an average rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA opened at $26.09 on Friday. The company has a market capitalization of $1.90 billion, a P/E ratio of -186.34 and a beta of 0.07. The business's 50-day moving average is $22.40 and its two-hundred day moving average is $21.37. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. During the same period last year, the business earned ($0.25) earnings per share. Kiniksa Pharmaceuticals's quarterly revenue was up 72.5% on a year-over-year basis. Analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals

In related news, insider Ross Moat sold 23,234 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $28.02, for a total value of $651,016.68. Following the completion of the transaction, the insider now owns 9,415 shares of the company's stock, valued at approximately $263,808.30. This represents a 71.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 242,768 shares of company stock worth $5,865,486 in the last three months. Company insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.